BioConnection announces that Lava Therapeutics (LAVA), a biotechnology company creating and developing next-generation γδ T cell engaging bispecific antibodies for the treatment of cancer, has selected BioConnection for GMP DP manufacturing. LAVA and BioConnection now work together to improve the treatment of cancer.

LAVA develops proprietary bispecific Vγ9Vδ2 T cell engagers for selected tumor targets. The opportunity for the company is to develop potent, safe and cost-effective biopharmaceuticals that arm the immune system to recognize and destroy tumor cells.
BioConnection full fills the needs of innovative (bio)pharmaceutical companies like LAVA by offering flexible state of the art development and GMP compliant manufacturing services for sterile Drug Products, both clinical and commercial.
BioConnection is currently expanding with a new large state-of-the-art production line. This benefits LAVA as it is not only possible to produce their product for clinical purposes but also enables LAVA to scale up to commercial production in time for the market – all within the same building.

“LAVA’s differentiated T cell engager platform has the potential to target oncology settings of high unmet need, based on cutting edge Dutch science. Therefore, we were looking for a supplier offering a fast, flexible and solution-driven approach for the GMP DP manufacturing. By cooperating with BioConnection, we can start our clinical trials on time”, said Steve Hurly, CEO of LAVA. “I am looking forward to working with BioConnection to translate our γδ T cell engager platform to the clinic.”
Alexander Willemse, CEO of BioConnection adds: “We are pleased to contribute to the innovative power and success of LAVA in the clinical phase and beyond by producing clinical trial material in our FDA/EMA certified manufacturing site. We look forward to working with LAVA’s team to further develop their exciting technology.”